A Phase 2/3 interventional study of Netarsudil and Placebo in Fuchs' Endothelial Dystrophy, sponsored by Price Vision Group. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-06.
Sponsored by Price Vision Group · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Fuchs' Endothelial Dystrophy with a site in United States — 9 open to participants now, 10 under way, 1 of them phase 3. Fuchs' Endothelial Dystrophy · United States.
Among the 40 studies in Fuchs' Endothelial Dystrophy with a site in United States, this one is the 27th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2019, is one of 3 in phase 2/3, and was the 16th registered.
92 studies on the registry are indexed under Fuchs' Endothelial Dystrophy; 27 are open to participants now.
Browse Fuchs' Endothelial Dystrophy studies →9 of the 40 studies in Fuchs' Endothelial Dystrophy with a site in United States are open now. Recruiting first, the newest first:
Emmecell · Sites in United States
Ages 21+
Design Therapeutics, Inc. · Sites in United States
Ages 30+
University of Miami · Sites in United States
Ages 18–80
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 21+
Oregon Health and Science University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Fuchs' Endothelial Dystrophy studies recruiting now, 16 (73%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 7 · Phase 4 3
First in 2005; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 50 across 62 interventional studies indexed under Fuchs' Endothelial Dystrophy.
Median enrollment 44 across the 32 interventional studies, 55 across the 8 observational. Of the 27 that completed or were terminated, 11 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 40 have an industry lead sponsor. The 10 most frequent:
Price Vision Group is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Price Vision Group has 2 studies filed under Fuchs' Endothelial Dystrophy — fewer than ten, so there is no comparison to draw.
5 of the studies in Fuchs' Endothelial Dystrophy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05275972Phase 3Stanford UniversityDescemet Endothelial Thickness Comparison Trial II | 2027-10-30 |
| NCT04440280Massachusetts Eye and Ear InfirmaryTargeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy | 2027-04-29 |
| NCT04258787Oregon Health and Science UniversityOCT in Fuchs' Dystrophy | 2027-06 |
| NCT07729137EmmecellStudy of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction | 2027-08 |
| NCT06261346University of MiamiPlasma Rich in Growth Factors in Corneal Endothelial Transplantation | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Fuchs' Endothelial Dystrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer.
Subjects with Fuchs endothelial dystrophy will have the central corneal endothelium and guttae-covered Descemet membrane surgically removed. Subjects will be randomized to use netarsudil or placebo eye drops once daily. Visual acuity, corneal clearing and central endothelial cell density will be monitored for the 3-month study duration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner
Drug: Netarsudil
Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.
Drug: Placebo
netarsudil opthalmic solution 0.02%
Also known as: Rhopressa
Placebo eye drops
Corneal Clearing After Endothelial Removal for Treatment of Fuchs Dystrophy
The outcome measure was the percentage area of the cornea that remained edematous after removal of the endothelium. At the time of surgery, the surgeon recorded the lengths of the major and minor axes of the approximately circular area of endothelium removal; these values were used to calculate the area of stripping. At each postoperative exam, the examiner recorded the lengths of the major and minor axes of the edematous area; these values were used to calculate the area of edema. The percentage that remained edematous at 5 weeks was calculated by dividing the area of edema at 5 weeks by the area stripped.
Time frame: 5 weeks
| Milestone | Netarsudil | Placebo |
|---|---|---|
| Started | 10 | 9 |
| Completed | 10 | 8 |
| Not completed | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
The outcome measure was the percentage area of the cornea that remained edematous after removal of the endothelium. At the time of surgery, the surgeon recorded the lengths of the major and minor axes of the approximately circular area of endothelium removal; these values were used to calculate the area of stripping. At each postoperative exam, the examiner recorded the lengths of the major and minor axes of the edematous area; these values were used to calculate the area of edema. The percentage that remained edematous at 5 weeks was calculated by dividing the area of edema at 5 weeks by the area stripped.
| percentage of area stripped | Netarsudil | Placebo |
|---|---|---|
| Corneal Clearing After Endothelial Removal for Treatment of Fuchs Dystrophy | 42 ± 45 | 43 ± 49 |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Netarsudil | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Placebo | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| Event | Netarsudil | Placebo |
|---|---|---|
| eye discomfortEye disorders | 2/10 | 3/9 |
| cystoid macular edemaEye disorders | 1/10 | 0/9 |
| microcystic corneal epithelial bullaeEye disorders | 1/10 | 0/9 |
| Age, Continuous(years) | Netarsudil | Placebo | Total |
|---|---|---|---|
| Mean | 65 ± 10 | 58 ± 17 | 62 ± 14 |
| Sex: Female, Male(Participants) | Netarsudil | Placebo | Total |
|---|---|---|---|
| Female | 10 | 8 | 18 |
| Male | 0 | 1 | 1 |
| Race and Ethnicity Not Collected(Participants) | Netarsudil | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Netarsudil | Placebo | Total |
|---|---|---|---|
| United States | 10 | 9 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Aug 2021, 25 months.
Results were first posted in Feb 2023, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil
Fuchs' Endothelial Dystrophy →
Price Vision Group